Akebia Therapeutics, Inc. (AKBA) [Rocket]

Date Filed	Type	Description
04/10/2020	GN	INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Akebia Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims.
03/27/2019	GN	Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy — Fundamental Analysis, Key Performance Indications
11/29/2018	GN	ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
10/30/2018	GN	Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics
07/06/2018	GN	INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. is Fair to Shareholders
06/06/2018	GN	Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic Software Enterprises, Jounce Therapeutics, and Akebia Therapeutics — Discovering Underlying Factors of Influence
05/09/2018	BW	Akebia Therapeutics Announces First Quarter 2018 Financial Results
04/09/2018	GN	Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
03/16/2018	GN	New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies — Factors of Influence, Major Initiatives and Sustained Production
03/12/2018	BW	Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
03/05/2018	BW	Akebia Therapeutics to Host Fourth Quarter and Full-Year 2017 Investor Update Call and Webcast
11/16/2017	BW	Akebia Therapeutics to Participate in Upcoming Investor Conferences